Beta Bionics officer proposes $153K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Stephen Feider, an officer of Beta Bionics, Inc. (BBNX), reported a proposed sale of 8,874 common shares, with an aggregate market value of $152,680.72 and an approximate sale date of November 11, 2026.
He lists the same 8,874 shares as acquired from the issuer through stock options on November 11, 2026, with cash payment. His reported common-stock sales during the prior three months were 744 shares for gross proceeds of $12,649 on November 9, 382 shares for $6,508 on November 5, and 6,675 shares for $129,595.13 on September 2, 2026.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Stock Options financial
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Rule 10b5-1 date is listed for Stephen Feider's BBNX sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.